Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Show other versions (1)

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
פורמט:	Journal article
שפה:	English
יצא לאור:	2001

פריטים דומים

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
מאת: Croucher, P, et al.
יצא לאור: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
מאת: Croucher, P, et al.
יצא לאור: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
מאת: Croucher, P, et al.
יצא לאור: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
מאת: Croucher, P, et al.
יצא לאור: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
מאת: Croucher, P, et al.
יצא לאור: (2002)

Osteoprotegerin and the development of myeloma bone disease
מאת: Croucher, P, et al.
יצא לאור: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
מאת: Shipman, C, et al.
יצא לאור: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
מאת: Vanderkerken, K, et al.
יצא לאור: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
מאת: Shipman, C, et al.
יצא לאור: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
מאת: Shipman, C, et al.
יצא לאור: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
מאת: De Leenheer, E, et al.
יצא לאור: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
מאת: Shipman, C, et al.
יצא לאור: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
מאת: Croucher, P, et al.
יצא לאור: (2003)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
מאת: Croucher, P, et al.
יצא לאור: (2002)

Role of osteoprotegerin (OPG) in cancer.
מאת: Holen, I, et al.
יצא לאור: (2006)

Bisphosphonates--mechanisms of action in multiple myeloma.
מאת: Shipman, C, et al.
יצא לאור: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
מאת: Shipman, C, et al.
יצא לאור: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
מאת: Shipman, C, et al.
יצא לאור: (2000)

The role of osteoprotegerin in breast and prostate cancer
מאת: Holen, I, et al.
יצא לאור: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
מאת: De Leenheer, E, et al.
יצא לאור: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
מאת: Shipman, C, et al.
יצא לאור: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
מאת: Shipman, C, et al.
יצא לאור: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
מאת: Holen, I, et al.
יצא לאור: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
מאת: Eaton, C, et al.
יצא לאור: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
מאת: Anđelković Zlatibor, et al.
יצא לאור: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
מאת: Huan Liu, et al.
יצא לאור: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
מאת: Mueller, G, et al.
יצא לאור: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
מאת: Mueller, G, et al.
יצא לאור: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
מאת: Edwards, C, et al.
יצא לאור: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
מאת: Holen, I, et al.
יצא לאור: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
מאת: Eaton, C, et al.
יצא לאור: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
מאת: Akshitha Devaraj, MBBS, et al.
יצא לאור: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
מאת: Aiken Dao, et al.
יצא לאור: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
מאת: Dongyeop Shin, et al.
יצא לאור: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
מאת: Locklin, R, et al.
יצא לאור: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
מאת: Waterman, E, et al.
יצא לאור: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
מאת: Dongzheng Gai, et al.
יצא לאור: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
מאת: Domingos Sousa, et al.
יצא לאור: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
מאת: Dirk Hose, et al.
יצא לאור: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
מאת: Lwin, S, et al.
יצא לאור: (2017)